The “bead’ goes on at Lynx therapeutics, as the company continues to build up its roster of collaborators for its microbead-based Megaclone DNA detection technology and to increase its revenues from these collaborations.

July 18 the company reported second-quarter revenues of $4.4 million, up 57 percent from the $2.8 million in revenues reported during the same period last year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.